Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Net Cash Flow: 2014-2025

Historic Net Cash Flow for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$14.9 million.

  • CytomX Therapeutics' Net Cash Flow fell 480.09% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 143.58%. This contributed to the annual value of $21.0 million for FY2024, which is 111.89% up from last year.
  • CytomX Therapeutics' Net Cash Flow amounted to -$14.9 million in Q3 2025, which was down 1,133.82% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Net Cash Flow ranged from a high of $137.8 million in Q1 2021 and a low of -$137.3 million during Q1 2023.
  • In the last 3 years, CytomX Therapeutics' Net Cash Flow had a median value of -$2.5 million in 2024 and averaged -$14.5 million.
  • In the last 5 years, CytomX Therapeutics' Net Cash Flow skyrocketed by 498.98% in 2024 and then slumped by 480.09% in 2025.
  • CytomX Therapeutics' Net Cash Flow (Quarterly) stood at -$30.8 million in 2021, then soared by 420.66% to $98.6 million in 2022, then slumped by 108.98% to -$8.9 million in 2023, then surged by 71.49% to -$2.5 million in 2024, then crashed by 480.09% to -$14.9 million in 2025.
  • Its last three reported values are -$14.9 million in Q3 2025, $1.4 million for Q2 2025, and $9.6 million during Q1 2025.